By Owen Tucker-Smith
Shares of TG Therapeutics rose after the company raised its guidance on better-than-expected sales of its multiple sclerosis drug.
Shares were up 7.7% Tuesday to $29.79. The stock is about 18% below its 52-week high of $36.84.
The company said Briumvi, its multiple sclerosis drug, brought in $103.6 million in the fourth quarter and $310 million in 2024. In November, the company said it expected between $300 million and $305 million from the drug for the year.
TG Therapeutics also said it expects total global revenue around $540 million in 2025. Briumvi will bring in $525 million in the U.S., a 69% jump from the drug's 2024 sales.
The company noted that in the coming year, it plans to enroll participants in an ongoing trial testing Briumvi in diseases outside of multiple sclerosis.
"We believe Briumvi is well positioned to continue to grow and provide value to patients and physicians," said Chief Executive Michael Weiss.
Write to Owen Tucker-Smith at owen.tucker-smith@wsj.com
(END) Dow Jones Newswires
January 14, 2025 15:51 ET (20:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。